List of Clinical Research Companies in China - 5

普瑞盛（北京）医药科技开发有限公司（GCP ClinPlus Co.，Ltd.），简称普瑞盛，是中国顶尖的医药产品临床研究服务提供商。经过十六年的发展，逐步融合发展成为今天中国规模和综合实力均名列前茅的，既能够提供本土服务，又能直接提供境外跨国服务的综合临床研究服务公司。 普瑞盛拥有200多名全职员工，覆盖北京、上海、广州、南京、长沙、武汉、成都、西安、沈阳、天津、太原、石家庄、哈尔滨、新疆等10多个城市，并在美国建立了分公司。 普瑞盛致力于提供全方位的、符合国际标准的、充分利用人脉和地域资源的精准临床研究服务方案。 • CRO领域已参与1000+项临床研究（200+项全方位的临床服务） • 中国领先的数据统计团队 • 丰富的大型药物临床试验操作经验 • 专业的医疗器械临床研究服务团队 • 全方位的医学支持团队 • 丰富的CFDA答辩经验 团队朝气蓬勃，经验丰富，专业功底深厚。经过行业内十多年的积累，普瑞盛得到了众多知名企业的认可，目前客户遍布国内外排名前20的药企和医疗器械企业。

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services. As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide.

Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. It is a comprehensive provider founded by a group of top scientists, dedicated to providing innovative solutions in the biotech and biopharma space.

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com

NewDEL Biotech is a biotechnology company based in Shenzhen, China, established in 2021. The company focuses on the research and development of new drugs, with a particular emphasis on innovative drugs designed for tumors. NewDEL Biotech utilizes DNA Encoded Library technology to significantly improve the success rate of drug development.